Business Wire - Cypress Reaches Settlement with Glaxo Group Limited Relating to Ranitidine Oral Syrup Products
MADISON, Miss. — Cypress Pharmaceutical, Inc. today announced that it has reached a settlement with Glaxo Group Limited (Glaxo), part of the GlaxoSmithKline group of companies, resolving all disputes between the companies related to Cypress’ generic ranitidine oral solution products and Glaxo’s Zantac[R] syrup.
Under the terms of the settlement, Glaxo has agreed not to assert its patent against Cypress’ new alcohol-free formulation of its generic ranitidine oral syrup. Cypress expects to launch the product immediately upon receiving FDA approval. As a result of the settlement, the parties filed a stipulation to dismiss their patent litigation pending in the U.S. District Court for the Southern District of New York.
Most Popular
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
Creating Innovative New Growth Businesses Need Not Be as Random or Risky as Has Been Thought
Cypress Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development and marketing of prescription products to pharmaceutical wholesalers, chain drug stores, distributors, and other retail merchandisers in the United States. For more information about Cypress, visit www.cypressrx.com.
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
